Prabha Sridevan, the former chairperson of India’s Intellectual Property Appellate Board, says that just as Indian companies must obey American laws when selling their wares in the US, international pharmaceutical companies must similarly comply with Indian laws if they wish to do business in the world’s second most populous market
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
As trade secret filings rise due to AI development and economic espionage concerns, firms are relying on proactive counselling to help clients navigate disputes
IP firm leaders share why they remain positive in the face of falling patent applications from US filers, and how they are meeting a rising demand from China